Is ABVX or RVMD more profitable?

Revolution Medicines' return on equity of -83.22% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Revolution Medicines N/A -83.22% -59.06%

Does the media prefer ABVX or RVMD?

In the previous week, Abivax and Abivax both had 8 articles in the media. Revolution Medicines' average media sentiment score of 1.47 beat Abivax's score of 0.39 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ABVX or ONC?

BeOne Medicines has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A BeOne Medicines $5.34B 5.43 $286.93M $4.47 59.17

Is ABVX or ONC more profitable?

BeOne Medicines has a net margin of 8.94% compared to Abivax's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% BeOne Medicines 8.94% 12.06% 6.69%

Does the media refer more to ABVX or ONC?

In the previous week, BeOne Medicines had 5 more articles in the media than Abivax. MarketBeat recorded 13 mentions for BeOne Medicines and 8 mentions for Abivax. Abivax's average media sentiment score of 0.39 beat BeOne Medicines' score of -0.08 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BNTX or ABVX more profitable?

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Abivax N/A -99.02% -70.26%

Does the media favor BNTX or ABVX?

In the previous week, Abivax had 3 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Abivax and 5 mentions for BioNTech. BioNTech's average media sentiment score of 1.38 beat Abivax's score of 0.39 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ABVX or ROIV?

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Roivant Sciences $8.26M 2,615.84 -$299.77M -$0.60 N/A

Is ABVX or ROIV more profitable?

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media favor ABVX or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Roivant Sciences and 8 mentions for Abivax. Roivant Sciences' average media sentiment score of 1.59 beat Abivax's score of 0.39 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, ABVX or INSM?

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Insmed $606.42M 34.97 -$1.28B -$5.75 N/A

Is ABVX or INSM more profitable?

Abivax has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Abivax's return on equity of -99.02% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Insmed -144.44% -130.11% -51.57%

Does the media refer more to ABVX or INSM?

In the previous week, Insmed had 16 more articles in the media than Abivax. MarketBeat recorded 24 mentions for Insmed and 8 mentions for Abivax. Insmed's average media sentiment score of 1.22 beat Abivax's score of 0.39 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Abivax (ABVX) Competitors

$96.55 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$98.22 +1.67 (+1.73%)

As of 06/12/2026 07:57 PM Eastern

Compare

ABVX vs. RVMD, ONC, BNTX, ROIV, and INSM

Should you buy Abivax stock or one of its competitors? MarketBeat compares Abivax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abivax include Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Abivax compare to Revolution Medicines?

Abivax (NASDAQ:ABVX) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Abivax currently has a consensus price target of $130.08, indicating a potential upside of 34.72%. Revolution Medicines has a consensus price target of $123.72, indicating a potential downside of 19.59%. Given Abivax's higher possible upside, equities research analysts plainly believe Abivax is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Abivax and Abivax both had 8 articles in the media. Revolution Medicines' average media sentiment score of 1.47 beat Abivax's score of 0.39 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines' return on equity of -83.22% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Revolution Medicines	N/A	-83.22%	-59.06%

Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Abivax has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Revolution Medicines	$11.58M	2,824.94	-$1.13B	-$7.07	N/A

47.9% of Abivax shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Abivax on 10 of the 14 factors compared between the two stocks.

How does Abivax compare to BeOne Medicines?

Abivax (NASDAQ:ABVX) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Abivax has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BeOne Medicines had 5 more articles in the media than Abivax. MarketBeat recorded 13 mentions for BeOne Medicines and 8 mentions for Abivax. Abivax's average media sentiment score of 0.39 beat BeOne Medicines' score of -0.08 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to Abivax's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
BeOne Medicines	8.94%	12.06%	6.69%

Abivax currently has a consensus price target of $130.08, suggesting a potential upside of 34.72%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 47.46%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
BeOne Medicines	$5.34B	5.43	$286.93M	$4.47	59.17

Summary

BeOne Medicines beats Abivax on 13 of the 16 factors compared between the two stocks.

How does Abivax compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Abivax has lower revenue, but higher earnings than BioNTech. Abivax is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.05	-$1.29B	-$5.88	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

BioNTech currently has a consensus target price of $129.56, suggesting a potential upside of 43.10%. Abivax has a consensus target price of $130.08, suggesting a potential upside of 34.72%. Given BioNTech's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

In the previous week, Abivax had 3 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Abivax and 5 mentions for BioNTech. BioNTech's average media sentiment score of 1.38 beat Abivax's score of 0.39 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Abivax	N/A	-99.02%	-70.26%

Summary

BioNTech beats Abivax on 11 of the 16 factors compared between the two stocks.

How does Abivax compare to Roivant Sciences?

Abivax (NASDAQ:ABVX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Abivax currently has a consensus price target of $130.08, suggesting a potential upside of 34.72%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential upside of 11.82%. Given Abivax's higher possible upside, analysts clearly believe Abivax is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 4 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Roivant Sciences and 8 mentions for Abivax. Roivant Sciences' average media sentiment score of 1.59 beat Abivax's score of 0.39 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

47.9% of Abivax shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

Roivant Sciences beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Abivax compare to Insmed?

Abivax (NASDAQ:ABVX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 16 more articles in the media than Abivax. MarketBeat recorded 24 mentions for Insmed and 8 mentions for Abivax. Insmed's average media sentiment score of 1.22 beat Abivax's score of 0.39 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	17 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax presently has a consensus target price of $130.08, suggesting a potential upside of 34.72%. Insmed has a consensus target price of $212.50, suggesting a potential upside of 117.17%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Abivax has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Abivax's return on equity of -99.02% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Insmed beats Abivax on 11 of the 16 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.70B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-18.53	20.00	23.99	24.42
Price / Sales	N/A	305.33	511.38	110.47
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	14.70	8.32	10.65	6.82
Net Income	-$380.27M	$23.94M	$3.57B	$337.56M
7 Day Performance	-4.90%	1.84%	0.58%	1.17%
1 Month Performance	-15.70%	-0.04%	1.54%	3.16%
1 Year Performance	1,283.24%	44.82%	25.40%	30.58%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	3.3151 of 5 stars	$96.55 flat	$130.08 +34.7%	+1,283.2%	$7.70B	N/A	N/A	61	Gap Up
RVMD Revolution Medicines	1.7998 of 5 stars	$148.49 -0.5%	$123.72 -16.7%	+279.1%	$31.73B	$11.58M	N/A	250	Positive News Gap Down
ONC BeOne Medicines	4.1089 of 5 stars	$270.80 +0.3%	$390.00 +44.0%	-1.9%	$29.64B	$5.34B	60.58	12,000
BNTX BioNTech	4.5676 of 5 stars	$85.50 -2.9%	$129.56 +51.5%	-15.0%	$22.27B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.2976 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+165.4%	$20.49B	$8.26M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors

ABVX vs. RVMD, ONC, BNTX, ROIV, and INSM

How does Abivax compare to Revolution Medicines?

Summary

How does Abivax compare to BeOne Medicines?

Summary

How does Abivax compare to BioNTech?

Summary

How does Abivax compare to Roivant Sciences?

Summary

How does Abivax compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abivax (ABVX) Competitors

ABVX vs. RVMD, ONC, BNTX, ROIV, and INSM

How does Abivax compare to Revolution Medicines?

Do analysts rate ABVX or RVMD?

Does the media prefer ABVX or RVMD?

Is ABVX or RVMD more profitable?

Which has more volatility and risk, ABVX or RVMD?

Which has preferable earnings and valuation, ABVX or RVMD?

Do institutionals & insiders believe in ABVX or RVMD?

Summary

How does Abivax compare to BeOne Medicines?

Which has more volatility and risk, ABVX or ONC?

Do insiders & institutionals believe in ABVX or ONC?

Does the media refer more to ABVX or ONC?

Is ABVX or ONC more profitable?

Do analysts rate ABVX or ONC?

Which has better earnings & valuation, ABVX or ONC?

Summary

How does Abivax compare to BioNTech?

Which has stronger valuation & earnings, BNTX or ABVX?

Do analysts rate BNTX or ABVX?

Which has more volatility & risk, BNTX or ABVX?

Does the media favor BNTX or ABVX?

Do insiders and institutionals hold more shares of BNTX or ABVX?

Is BNTX or ABVX more profitable?

Summary

How does Abivax compare to Roivant Sciences?

Do analysts recommend ABVX or ROIV?

Which has preferable earnings & valuation, ABVX or ROIV?

Does the media favor ABVX or ROIV?

Do institutionals & insiders hold more shares of ABVX or ROIV?

Is ABVX or ROIV more profitable?

Which has more volatility & risk, ABVX or ROIV?

Summary

How does Abivax compare to Insmed?

Which has more risk and volatility, ABVX or INSM?

Do insiders & institutionals hold more shares of ABVX or INSM?

Which has better valuation & earnings, ABVX or INSM?

Does the media refer more to ABVX or INSM?

Do analysts recommend ABVX or INSM?

Is ABVX or INSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools